GlassScriptPhysician profile
Hai C DO
NPI 1245408764
$11,934.79
in general payments reported to CMS, 2019-2025
43 companies · $2,810 in 2025
The $2,810 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,076 · 2022: $929 · 2023: $3,755 · 2024: $3,364 · 2025: $2,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,706 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,706.36 |
| Education | $223.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,184.68 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,807.99 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,088.00 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $861.15 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $614.76 | 2021-2025 | |
| Novo Nordisk INC | $515.13 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $436.52 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Ucb, INC. | $419.06 | 2022-2025 | Fintepla, Briviact |
| Lilly USA, LLC | $396.54 | 2021-2025 | Amyvid, Kisunla, Mounjaro |
| Vanda Pharmaceuticals INC. | $392.87 | 2023-2025 | Fanapt, Hetlioz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.60 | 2021-2024 | |
| Lundbeck LLC | $310.93 | 2023-2025 | Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $281.26 | 2023-2025 | Aristada, Lybalvi |
| Exact Sciences Corporation | $232.70 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $214.68 | 2021-2023 | Breztri, Fasenra |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hai DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.